Results will be presented from ongoing clinical trials evaluating the ability of fluorescently labeled antibodies to enhance surgical resection in head and neck patients. Additionally, the inherent benefit of the technology will be examined during various stages of the surgical treatment workflow. Individual cases demonstrating patient benefit will be presented. In order to advance the field of fluorescence-guided surgery for oncologic resection, it is critical to investigate all areas of clinical application to maximize patient benefit.